Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol Journal Article
| Authors: | Sezgin, C.; Uygur, E.; Parlak, Y.; Karatay, B.; Barutca, S.; Dirican, A.; Sozen, T. S.; Arslan, G.; Harmansah, C.; Toklu, T.; Avcibasi, U.; Muftuler, Z. B.; Aras, O.; Gumuser, G. |
| Article Title: | Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol |
| Abstract: | This study presents a novel radiolabeling technique for [161Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [116 Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% +/- 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies. |
| Keywords: | dosimetry; resistant prostate-cancer; y-90; prostate-specific membrane antigen; in-111; targeted radionuclide therapy; terbium-161 |
| Journal Title: | Journal of Radioanalytical and Nuclear Chemistry |
| ISSN: | 0236-5731 |
| Publisher: | Springer |
| Publication status: | Online ahead of print |
| Date Published: | 2025-09-01 |
| Online Publication Date: | 2025-09-01 |
| Language: | English |
| ACCESSION: | WOS:001561272300001 |
| DOI: | 10.1007/s10967-025-10352-3 |
| PROVIDER: | wos |
| Notes: | Article; Early Access -- Source: Wos |
